Breast Cancer Clinical Trial
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Eligibility Criteria
Inclusion Criteria:
Pathologically confirmed invasive breast cancer, clinically stage I-II.
Clinically lymph node negative
Eligible for anti-endocrine treatment (per medical oncologist)
Postmenopausal women
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
Progesterone receptor negativity
High grade tumor
Synchronous non-breast malignancy
Receiving any other investigational agents that could impact the efficacy of this trial regimen
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study
Uncontrolled intercurrent illness
Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
